Galliprant is a drug owned by ELANCO US INC. It is protected by 5 US drug patents filed from 2021 to 2035. Out of these, 4 patents are active and 1 patent has expired. Details of Galliprant’s patents and their expiration are given below.
| Drug Patent Number | Drug Patent Expiry | Status |
|---|---|---|
 | ||
| US11369621 | 05 Mar, 2035 | Active |
| US7960407 | 10 Jul, 2029 | Active |
| US6710054 | 15 Oct, 2021 | Expired |
Exclusivity Information
Galliprant holds 1 exclusivity out of which 1 has expired. Details of Galliprant's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| NCE | Mar 20, 2021 |
Galliprant Petitions
Details of Galliprant's suitability petitions are listed below.
| Petitioner | Action | Date of Action | Description |
|---|---|---|---|
 | |||
| Aurora Pharmaceutical, Inc. | Approved | 31 Aug, 2023 | The proposed change is for an oral solution ; the RLNAD is approved as tablets in 20 mg, 60 mg, and 100 mg tablet strengths. The RLNAD's 20 mg and 60 mg tablets are scored, whereas the RLNAD's 100 mg tablet is unscored. |
About Galliprant
Galliprant is a drug
owned by ELANCO US INC.
Galliprant uses
Grapiprant as the active
ingredient.
Active Ingredient:
Galliprant uses
Grapiprant as the active ingredient.
Check out other Drugs and Companies using
Grapiprant ingredient.